Edition:
India

TapImmune Inc (TPIV.OQ)

TPIV.OQ on NASDAQ Stock Exchange Capital Market

10.29USD
11:31pm IST
Change (% chg)

$0.31 (+3.11%)
Prev Close
$9.98
Open
$9.99
Day's High
$10.29
Day's Low
$9.70
Volume
45,726
Avg. Vol
79,915
52-wk High
$13.54
52-wk Low
$2.60

Latest Key Developments (Source: Significant Developments)

Tapimmune And Marker Therapeutics Announce Entry Into Merger Agreement
Tuesday, 15 May 2018 

May 15 (Reuters) - TapImmune Inc ::TAPIMMUNE AND MARKER THERAPEUTICS ANNOUNCE ENTRY INTO MERGER AGREEMENT, CREATING A TRANSFORMATIONAL IMMUNO-ONCOLOGY PLATFORM.TAPIMMUNE - MARKER STOCKHOLDERS RECEIVE NEW SHARES, WARRANTS OF CO'S STOCK RELATED TO DEAL EQUAL TO NUMBER OF CO SHARES, WARRANTS OUTSTANDING AT DEAL CLOSE.TAPIMMUNE INC - PROPOSED DEAL TO BE A MERGER-OF-EQUALS UNDER WHICH STOCKHOLDERS OF TAPIMMUNE AND MARKER WILL EACH OWN ABOUT 50% OF COMBINED COMPANY.  Full Article

Iroquois Capital Management LLC Reports A 5.5 Pct Stake In TapImmune As Of April 4
Thursday, 5 Apr 2018 

April 4 (Reuters) - TapImmune Inc ::IROQUOIS CAPITAL MANAGEMENT LLC REPORTS A 5.5 PCT STAKE IN TAPIMMUNE AS OF APRIL 4 - SEC FILING.PURCHASED TAPIMMUNE'S SECURITIES BELIEVING WHEN PURCHASED, THEY WERE "UNDERVALUED" & WERE AN "ATTRACTIVE INVESTMENT OPPORTUNITY".  Full Article

Tapimmune Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Treating Triple-Negative Breast Cancer
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Tapimmune Inc ::TAPIMMUNE ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2 CLINICAL TRIAL FOR TREATING TRIPLE-NEGATIVE BREAST CANCER FUNDED BY U.S. DEPARTMENT OF DEFENSE.TAPIMMUNE INC - 280-PATIENT PHASE 2 TRIAL, SPONSORED BY MAYO CLINIC, RECEIVED $13.3 MILLION IN GRANT FUNDING FROM U.S. DEPARTMENT OF DEFENSE.TAPIMMUNE - ‍INTERIM IMMUNOGENICITY RESULTS FROM ONGOING STUDY EVALUATING TPIV200 IN RANDOMIZED DOSING TRIAL IN TNBC ANTICIPATED IN FIRST HALF OF 2018.  Full Article

Tapimmune Q3 loss earnings per share $0.39‍​
Thursday, 16 Nov 2017 

Nov 15 (Reuters) - Tapimmune Inc :Tapimmune provides third quarter 2017 corporate and clinical update.Tapimmune Inc - qtrly loss earnings per share $0.39‍​.  Full Article

TapImmune says 280-patient efficacy trial sponsored by Mayo Clinic evaluating TPIV200 efficacy expected to begin by year end 2017​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - TapImmune Inc ::TapImmune Inc - 280-patient efficacy trial sponsored by Mayo Clinic evaluating TPIV200 efficacy expected to begin by year end 2017​.TapImmune - ‍enrolled final patient in randomized Phase 2 clinical study of novel T-cell vaccine candidate TPIV200.TapImmune Inc - ‍look forward to reporting interim immunogenicity results in first half of 2018 from TPIV200 study​.  Full Article

Tapimmune advances TPIV 200 phase 2 triple-negative breast cancer trial
Wednesday, 15 Feb 2017 

Tapimmune Inc : Tapimmune advances TPIV 200 phase 2 triple-negative breast cancer trial after favorable DSMB safety review . Tapimmune Inc - will be enrolling remaining patients in trial at 12 clinical centers in U.S. with enrollment completion targeted for end of 2017 .Tapimmune Inc- have two additional phase 2 trials now enrolling or about to enroll ovarian and triple-negative breast cancer patients.  Full Article

BRIEF-Tapimmune And Marker Therapeutics Announce Entry Into Merger Agreement

* TAPIMMUNE AND MARKER THERAPEUTICS ANNOUNCE ENTRY INTO MERGER AGREEMENT, CREATING A TRANSFORMATIONAL IMMUNO-ONCOLOGY PLATFORM

No consensus analysis data available.